Eran Broshy - Nov 26, 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Corinna Liebowitz, Attorney-in-Fact
Stock symbol
TBPH
Transactions as of
Nov 26, 2025
Transactions value $
-$447,920
Form type
4
Date filed
12/1/2025, 07:02 PM
Previous filing
Nov 14, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BROSHY ERAN Director C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Corinna Liebowitz, Attorney-in-Fact 2025-12-01 0001256230

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Sale -$280K -14K -18.87% $20.00 60.2K Nov 26, 2025 Direct F1
transaction TBPH Ordinary Shares Sale -$310K -15.5K -25.75% $20.00 44.7K Nov 26, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Options Exercise $142K +14K +20.66% $10.15 81.7K Nov 26, 2025 Ordinary Shares 14K $10.15 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F2 The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
F3 This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).
F4 Reflects solely exercisable, vested Share Options following reported transaction.